A. Wozniak

A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.

P. LoRusso, R. Parchment, S. Gadgeel, 2007, Investigational new drugs.

A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor

P. LoRusso, R. Parchment, S. Gadgeel, 2006, Investigational New Drugs.

Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors.

A. Shields, S. Gadgeel, E. Heath, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study

P. Deluca, S. Gadgeel, E. Heath, 2007 .